Rationale and design of the TADCLOT trial: A double blind randomized controlled trial comparing twice a day clopidogrel vs ticagrelor in reducing major cardiac events in patients with acute ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention
Study context
- Population
- STEMI patients undergoing primary percutaneous coronary intervention (PCI), randomized following successful PCI when deemed suitable for dischargepatients planned to complete the trial
- Participants
- 2,200 patients
- Planned comparison
- Ticagrelor over twice-daily clopidogrel in reducing major adverse cardiac events (MACE) in STEMI patients undergoing primary percutaneous coronary intervention (PCI)
- Primary endpoint
- rate of major adverse cardiac events (MACE), a composite of death, myocardial infarction, stent thrombosis, target lesion revascularization, or stroke
- Follow-up
- 30 days following randomization
Methodological detailssuperiority trial, National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
- Superiority trial
- National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
- Enrollment has reached
- 88%
Original publication
Rationale and design of the TADCLOT trial: A double blind randomized controlled trial comparing twice a day clopidogrel vs ticagrelor in reducing major cardiac events in patients with acute STEMI undergoing primary percutaneous coronary intervention. Am Heart J. Published 12 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →